Aerska Overview

  • Year Founded
  • 2025

Year Founded

  • Status
  • Private

  • Employees
  • 24

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $49M

  • Investors
  • 17

Aerska General Information

Description

Developer of RNA medicines designed to treat, delay, and prevent diseases of the brain. The company silences the genes that cause harm, aims to preserve minds, protect memories, and enable loved ones to live healthy and long lives, and offers unprecedented potency, durability, and precision for hitting disease targets at their origin, intracellularly, enabling healthcare professionals to provide effective care and improve patient outcomes.

Contact Information

Website
www.aerska.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 251 Little Falls Drive
  • Wilmington, DE 19808
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Drug Delivery
Vertical(s)
Corporate Office
  • 251 Little Falls Drive
  • Wilmington, DE 19808
  • United States

Aerska Timeline

2026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Aerska Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series A) 18-May-2026 $49M Completed Generating Revenue
1. Seed Round 03-Jun-2025 Completed Generating Revenue
To view Aerska’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Aerska Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Aerska Investors (17)

Investor Name Investor Type Holding Investor Since Participating Rounds
EQT Life Sciences Venture Capital Minority
Global Health Investment Corporation Venture Capital Minority
Iaso Ventures Venture Capital Minority
Ada Ventures Venture Capital Minority
Age 1 Venture Capital Minority
You’re viewing 5 of 17 investors. Get the full list »

Aerska FAQs

  • When was Aerska founded?

    Aerska was founded in 2025.

  • Where is Aerska headquartered?

    Aerska is headquartered in Wilmington, DE.

  • What is the size of Aerska?

    Aerska has 24 total employees.

  • What industry is Aerska in?

    Aerska’s primary industry is Drug Discovery.

  • Is Aerska a private or public company?

    Aerska is a Private company.

  • What is Aerska’s current revenue?

    The current revenue for Aerska is .

  • How much funding has Aerska raised over time?

    Aerska has raised $70M.

  • Who are Aerska’s investors?

    EQT Life Sciences, Global Health Investment Corporation, Iaso Ventures, Ada Ventures, and Age 1 are 5 of 17 investors who have invested in Aerska.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process